GlassScriptPhysician profile
David A Coffey
NPI 1437474665
$3,052.59
in general payments reported to CMS, 2019-2025
26 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.51 · 2022: $753 · 2023: $864 · 2024: $685 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.45 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $303.98 | 2022-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $285.32 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $267.68 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $260.98 | 2022-2024 | |
| Novo Nordisk INC | $175.19 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $159.00 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.75 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $80.28 | 2022-2023 | Jardiance, Emgality |
| Astellas Pharma US INC | $64.21 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $54.64 | 2022-2023 | Xarelto |
| Corcept Therapeutics | $52.93 | 2025 | Korlym |
| Lundbeck LLC | $49.44 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $45.75 | 2019-2023 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.73 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $30.40 | 2022-2023 | |
| Atricure, INC. | $25.81 | 2025 | Atriclip Laa Exclusion System |
| Boston Scientific Corporation | $23.27 | 2025 | Watchman Access System |
| Dexcom, INC. | $17.24 | 2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $17.02 | 2022 | |
| Viatris Specialty LLC | $16.27 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $14.74 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 2022 | |
| Sumitomo Pharma America, INC. | $12.51 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.